

**510(k) Summary**  
**Lucent®**

**510(k) Number K122967**

**FEB 21 2013**

***Manufacturer Identification***

**Submitted by:**

Spinal Elements, Inc.  
2744 Loker Ave. W., Suite 100  
Carlsbad, CA 92010  
760-607-0121

**Contact Information:**

Benjamin A. Kimball  
Regulatory Affairs Manager  
Spinal Elements, Inc.  
2744 Loker Ave. W., Suite 100  
Carlsbad, CA 92010  
760-607-1816  
Bkimball@spinalelements.com

**Date Prepared:**

November 9, 2012

**Proprietary Name**

Lucent®

**Common Name**

Intervertebral Body Fusion Device

**Device Classification**

21 CFR 888.3080 (Intervertebral Body Fusion Device)

**Proposed Regulatory Class**

Class II

**Device Product Code**

MAX

**Purpose of this Special 510(k)**

This Special 510(k) seeks clearance for a modification (larger sizes - line addition) to Lucent® intervertebral body fusion devices previously cleared under K071724, K073348, and K110632.

***Device Description***

This product is an intervertebral body fusion device for use in lumbar spinal surgery. It may also be referred to as an interbody device or interbody cage. The device is generally box-shaped with various holes throughout its design to allow for the placement of autograft. The exterior of the device has “teeth” or other generally sharp engagement members on the superior and inferior surfaces to help prevent the device from migrating once it is surgically positioned. The devices may be manufactured from titanium (Ti-6Al-4V) conforming to ASTM F 136 or ISO 5832-3, polyetheretherketone materials conforming to ASTM F 2026 or polyetheretherketone with a plasma sprayed coating of commercially pure titanium (per ASTM F 1580) on their superior and inferior surfaces.

***Intended Use of the Device***

Lucent® intervertebral body fusion devices are intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved levels. These patients may have had a previous non-fusion spinal surgery at the involved spinal level(s).

This device is intended to be used with supplemental spinal fixation systems that have been cleared for use in the lumbosacral spine (i.e., posterior pedicle screw and rod systems, anterior plate systems, and anterior screw and rod systems).

This device is intended to be used with autogenous bone graft. Patients must have undergone a regimen of at least six (6) months non-operative treatment prior to being treated with this device.

***Performance Data***

The following testing was performed:  
Static torsion, ASTM F 2077

***Substantial Equivalence***

The subject Lucent intervertebral body fusion device was shown to be substantially equivalent to previously cleared devices in indications for use, design, function, and materials used.

- Lucent 510(k) K071724, K073348 and K110632



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-002

February 21, 2013

Spinal Elements, Incorporated  
% Mr. Benjamin A. Kimball  
Regulatory Affairs Manager  
2744 Loker Avenue West, Suite 100  
Carlsbad, California 92010

Re: K122967  
Trade/Device Name: Lucent®  
Regulation Number: 21 CFR 888.3080  
Regulation Name: Intervertebral body fusion device  
Regulatory Class: Class II  
Product Code: MAX  
Dated: September 24, 2012  
Received: September 25, 2012

Dear Mr. Kimball:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**ErinFDKeith**

Mark N. Melkerson  
Director  
Division of Orthopedic Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**Indications for Use**

**510(k) K:**

**Device Name:** Lucent®

**Indications for Use:**

Lucent intervertebral body fusion devices are intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved levels. These patients may have had a previous non-fusion spinal surgery at the involved spinal level(s).

This device is intended to be used with supplemental spinal fixation systems that have been cleared for use in the lumbosacral spine (i.e., posterior pedicle screw and rod systems, anterior plate systems, and anterior screw and rod systems).

This device is intended to be used with autogenous bone graft. Patients must have undergone a regimen of at least six (6) months non-operative treatment prior to being treated with this device.

Prescription Use  X   
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER  
PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

**Stephanie Bechtold -S**

Page 1 of 1

---

(Division Sign-Off)

Division of Orthopedic Devices

510(k) Number: K122967